Millions of people across the country have been prescribed the blood thinner Pradaxa (Dabigatran) to treat an irregular heartbeat. Recently, thousands of adverse reports related to the drug have led to a multidistrict lawsuit against its manufacturer.
In 2011, 3,781 adverse effects and 542 deaths associated with Pradaxa were reported to the FDA. Dangerous reactions included gastrointestinal bleeding, hemorrhaging, and heart attack. In fact, Pradaxa had the highest number of deaths among all drugs reported last year.
Hundreds of patients have joined a multidistrict lawsuit to go up against the dangerous drug and its manufacturer, Boehringer Ingleheim. In about a year, a panel of judges will hear from patients chosen to represent the hundreds of claims currently filed by people who suffered adverse reactions to Pradaxa.
The FDA is currently conducting a safety review of Pradaxa to determine whether the reports of bleeding are occurring more commonly than would be expected. The FDA says that patients prescribed Pradaxa should not stop taking it without talking to their healthcare provider first.